CuraScientific Corp (CSTF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CuraScientific Corp (CSTF) trades at $0.00 with AI Score 42/100 (Grade C). CuraScientific Corp, founded in 2020 and based in Coachella, California, specializes in the production, distribution, and retail of cannabis products under JW Brands and Chad Enterprises. Market cap: $377,345, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CSTF: CSTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSTF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CSTF: the 1 perspectives are evenly split.
How is this calculated? →CuraScientific Corp (CSTF) Healthcare & Pipeline Overview
CuraScientific Corp. (CSTF), established in 2020, operates within the healthcare sector, focusing on the production, distribution, and retail of cannabis, CBD, kava, and kratom products under its JW Brands and Chad Enterprises labels from its Coachella, California base. The company navigates the evolving specialty and generic drug manufacturing landscape.
What Is the Investment Thesis for CSTF?
CuraScientific Corp. (CSTF) operates in the dynamic and growing market for cannabis and botanical products, positioning itself through its JW Brands and Chad Enterprises labels. A key value driver is its diversified product portfolio, which includes cannabis, CBD, kava, and kratom, potentially mitigating risks associated with reliance on a single product category. The company's relatively recent founding in 2020 allows for agility in adapting to market trends and regulatory changes within the specialty drug manufacturing and retail sectors. However, the company's current financial metrics present significant challenges, including a negative profit margin of -15299.2% and a gross margin of -3298.1%, indicating substantial operational inefficiencies or early-stage investment without corresponding revenue. The market capitalization of 377K suggests a very nascent or illiquid market presence. Growth catalysts would hinge on successful market penetration for its brands, potential expansion into new geographic markets, or strategic partnerships to improve distribution. Risks include intense competition, evolving regulatory landscapes for cannabis and other botanicals, and the critical need to achieve profitability and positive gross margins. The OTC Other tier listing also implies challenges with liquidity and disclosure, requiring thorough due diligence from investors.
Based on FMP financials and quantitative analysis
CSTF Key Highlights
- Market Capitalization: $0.00B, indicating a very small or illiquid market presence.
- Profit Margin: -15299.2%, reflecting substantial net losses relative to revenue.
- Gross Margin: -3298.1%, suggesting that the cost of goods sold significantly exceeds revenue.
- Beta: -3.96, indicating an inverse relationship with the broader market, though this could be skewed by low liquidity or specific trading patterns.
- Employee Count: 2 employees, highlighting a highly lean operational structure.
Who Are CSTF's Competitors?
CSTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSTF's Key Strengths?
- Diversified product portfolio including cannabis, CBD, kava, and kratom.
- Established brand names (JW Brands, Chad Enterprises) in the cannabis market.
- Agile operational structure with a small employee base (2 employees).
What Are CSTF's Weaknesses?
- Extremely negative profit margin (-15299.2%) and gross margin (-3298.1%) indicating severe unprofitability.
- Very small market capitalization ($0.00B) suggesting limited scale and market presence.
- Limited employee base (2 employees) may constrain growth and operational capacity.
- OTC Other tier listing implies challenges with liquidity and disclosure.
What Could Drive CSTF Stock Higher?
- Potential for new state-level cannabis legalization could open new market opportunities for distribution and sales.
- Introduction of new product lines or botanical extracts beyond current offerings, potentially expanding market reach.
- Efforts to improve operational efficiency and reduce the significant negative gross and profit margins.
- Any future financial filings or news releases that provide clarity on performance and strategic direction.
What Are the Key Risks for CSTF?
- Sustained unprofitability, as evidenced by extremely negative profit and gross margins, threatening long-term viability.
- Intense competition in the rapidly evolving cannabis and botanical products market from larger, better-funded entities.
- Adverse changes in regulatory frameworks for cannabis, CBD, kava, or kratom could impact operations and market access.
- Challenges related to liquidity and investor confidence due to trading on the OTC Other tier with unknown disclosure status.
- Limited resources and a small employee base (2 employees) may hinder scalability and ability to capitalize on growth opportunities.
What Are the Growth Opportunities for CSTF?
- Growth opportunity 1: Expansion of Product Portfolio into New Botanical Extracts: CuraScientific could explore the integration of additional botanicals with recognized wellness benefits into its product lineup, beyond its current offerings of cannabis, CBD, kava, and kratom. This strategy could tap into the broader natural products market, which is projected to grow significantly, with certain segments like adaptogens and nootropics experiencing robust demand. By identifying and developing products from botanicals with strong scientific backing or established traditional use, CuraScientific could diversify revenue streams and appeal to a wider consumer base seeking natural health solutions. The timeline for such expansion would involve research, regulatory navigation, and product development, potentially spanning 1-3 years for market entry.
- Growth opportunity 2: Geographic Market Expansion within Regulated Cannabis States: As more U.S. states legalize cannabis for medical or recreational use, CuraScientific has the opportunity to expand its distribution and retail footprint beyond its current operational base. The U.S. legal cannabis market is projected to reach tens of billions of dollars in the coming years, presenting substantial growth potential. By strategically entering newly legalized or underserved state markets, CuraScientific could leverage its existing brand infrastructure (JW Brands, Chad Enterprises) to capture new customer segments. This would require navigating diverse state-specific regulatory frameworks, securing licenses, and establishing local supply chains, a process that could unfold over a 2-5 year horizon.
- Growth opportunity 3: Development of Branded Retail Experiences: Establishing proprietary retail locations or partnering with specialized dispensaries could enhance brand visibility and direct-to-consumer sales for JW Brands and Chad Enterprises. A branded retail experience allows for greater control over customer education, product presentation, and brand messaging, fostering customer loyalty in a competitive market. This strategy could emulate successful models seen in other consumer goods sectors, creating a unique purchasing environment. While requiring significant capital investment and operational expertise, a well-executed retail strategy could significantly boost market share and brand equity over a 3-5 year period, capitalizing on the growing consumer demand for curated shopping experiences in the cannabis space.
- Growth opportunity 4: Strategic Partnerships for Enhanced Distribution and Manufacturing: Given its lean operational structure with two employees, CuraScientific could pursue strategic alliances with established cultivators, manufacturers, or distribution networks. Such partnerships could provide access to larger production capacities, broader distribution channels, and specialized expertise, accelerating market penetration and reducing operational costs. Collaborations could also extend to research and development, particularly for novel product formulations in the CBD, kava, or kratom segments. These alliances could be crucial for scaling operations efficiently and effectively, allowing CuraScientific to compete more robustly against larger players, with initial benefits potentially realized within 1-2 years.
- Growth opportunity 5: Focus on Niche Medical or Wellness Applications for CBD/Kratom: CuraScientific could differentiate itself by targeting specific medical or wellness applications for its CBD, kava, and kratom products, moving beyond general recreational use. This could involve developing specialized formulations aimed at areas like pain management, anxiety relief, or sleep disorders, backed by scientific research or anecdotal evidence. By focusing on a niche, the company could build a reputation as a trusted provider in a specific therapeutic area, potentially commanding higher margins. This strategy would require investment in product development, quality control, and potentially clinical studies, positioning the company for growth in specialized health markets over a 3-6 year timeframe.
What Opportunities Does CSTF Have?
- Expansion into new geographic markets as cannabis legalization progresses.
- Development of new botanical products or specialized formulations.
- Strategic partnerships to enhance distribution, manufacturing, or R&D.
- Growing consumer demand for alternative wellness and botanical products.
What Threats Does CSTF Face?
- Intense competition from larger, more established players in the cannabis and botanical markets.
- Evolving and complex regulatory landscape for cannabis, CBD, kava, and kratom.
- Challenges in achieving profitability and positive cash flow given current financial metrics.
- Liquidity and investor confidence issues associated with OTC Other tier trading.
What Are CSTF's Competitive Advantages?
- Proprietary brand names (JW Brands, Chad Enterprises) in the cannabis market.
- Diversified product portfolio including cannabis, CBD, kava, and kratom, reducing reliance on a single product.
- Early mover advantage in specific segments of the evolving botanical products market since its founding in 2020.
What Does CSTF Do?
CuraScientific Corp., headquartered in Coachella, California, was established in 2020, marking its entry into the rapidly evolving market for cannabis and related botanical products. The company's core business revolves around the comprehensive lifecycle of cannabis products, encompassing their production, distribution, and retail operations. These offerings are primarily marketed under two distinct brand names: JW Brands and Chad Enterprises, catering to specific segments within the cannabis consumer base. Beyond its foundational focus on cannabis, CuraScientific has strategically diversified its product portfolio to include other botanical derivatives known for their therapeutic or recreational properties. This expansion includes cannabidiol (CBD), a non-psychoactive compound derived from cannabis, which has gained significant traction for its potential health benefits. Furthermore, the company deals in kava and kratom, two botanicals with established traditional uses, broadening its appeal to a wider consumer demographic interested in natural wellness and alternative products. The company's operational history includes a significant corporate rebranding effort; prior to April 2023, CuraScientific Corp. conducted its business activities under the name Boon Industries, Inc. This name change signifies an evolution in its corporate identity and potentially its strategic direction within the healthcare and specialty drug manufacturing sectors. Operating with a lean team of two employees, CuraScientific manages its supply chain and market presence from its base in Coachella, positioning itself to serve the burgeoning demand for regulated cannabis and botanical products across various distribution channels. The company's strategy appears to center on leveraging its brand presence and product diversification to capture market share in a competitive and highly regulated industry.
What Products and Services Does CSTF Offer?
- Produces cannabis products under the JW Brands and Chad Enterprises names.
- Distributes cannabis products to various retail channels.
- Engages in the retail sale of cannabis products.
- Offers cannabidiol (CBD) products.
- Provides kava products.
- Sells kratom products.
- Operated as Boon Industries, Inc. prior to April 2023.
How Does CSTF Make Money?
- Generates revenue through the sale of cannabis products under its proprietary brands.
- Sells diversified botanical products including CBD, kava, and kratom.
- Operates across the production, distribution, and retail segments of the cannabis and botanical market.
What Industry Does CSTF Operate In?
CuraScientific Corp. operates within the "Drug Manufacturers - Specialty & Generic" industry, specifically focusing on the production and distribution of cannabis, CBD, kava, and kratom. This segment is characterized by rapid innovation, evolving consumer preferences, and a complex regulatory environment, particularly concerning cannabis. The broader healthcare sector is witnessing increasing demand for alternative wellness products, driving growth in botanical extracts. However, the market is highly fragmented with numerous players ranging from large pharmaceutical companies exploring cannabinoid-based drugs to smaller, specialized producers. CuraScientific's positioning with its JW Brands and Chad Enterprises names places it in direct competition with established cannabis brands and emerging botanical product companies. The challenge for CuraScientific lies in differentiating its offerings and achieving economies of scale in a market where regulatory compliance and product quality are paramount.
Who Are CSTF's Key Customers?
- Consumers seeking recreational cannabis products.
- Individuals interested in the wellness benefits of CBD, kava, and kratom.
- Retail dispensaries and other distribution partners for its branded products.
Company Profile
CuraScientific Corp operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Coachella, US. The company is led by CEO Samuel L. Berry. CSTF has traded publicly since 1998.
CuraScientific Corp (CSTF) Valuation Context
Valued at 377K, CSTF is classified as a micro-cap stock. Relative to its peer group, CSTF's quantitative score of 42/100 is below the peer average of 66/100.
ROE 8%Key Financial Metrics
Return on equity for CuraScientific Corp stands at 7.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -71.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 4/9Financial Health
CuraScientific Corp's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 66.06 places it in the safe zone, indicating low near-term bankruptcy risk.
CSTF Financials
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio including cannabis, CBD, kava, and kratom.
- Established brand names (JW Brands, Chad Enterprises) in the cannabis market.
- Agile operational structure with a small employee base (2 employees).
- Upcoming: Potential for new state-level cannabis legalization could open new market opportunities for distribution and sales.
Bear Case
- Extremely negative profit margin (-15299.2%) and gross margin (-3298.1%) indicating severe unprofitability.
- Very small market capitalization ($0.00B) suggesting limited scale and market presence.
- Limited employee base (2 employees) may constrain growth and operational capacity.
- OTC Other tier listing implies challenges with liquidity and disclosure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CSTF Latest News
No recent news available for CSTF.
CSTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSTF.
Price Targets
Wall Street price target analysis for CSTF.
CSTF MoonshotScore
What does this score mean?
The MoonshotScore rates CSTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Samuel L. Berry
CEO
Samuel L. Berry serves as the leader of CuraScientific Corp., overseeing its operations and strategic direction from its Coachella, California headquarters. With the company operating with a lean team of two employees, Mr. Berry's role likely encompasses a broad range of responsibilities, from product development and distribution strategy to financial oversight and regulatory compliance within the specialized healthcare and botanical products sector. His leadership is critical in navigating the complex landscape of cannabis, CBD, kava, and kratom markets, which are characterized by evolving regulations and intense competition. Specific details regarding his prior career history, educational background, or previous executive roles are not publicly available in the provided data.
Track Record: Under Samuel L. Berry's leadership, CuraScientific Corp. has established its presence in the cannabis and botanical products market since its founding in 2020, including the rebranding from Boon Industries, Inc. in April 2023. His tenure has seen the company focus on the production, distribution, and retail of products under JW Brands and Chad Enterprises, alongside offerings in CBD, kava, and kratom. Specific achievements, strategic decisions, or financial milestones directly attributable to his leadership are not detailed in the provided information.
CSTF OTC Market Information
CuraScientific Corp. (CSTF) trades on the OTC Other tier, which represents the lowest and most speculative segment of the OTC market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and minimum share prices, companies on the OTC Other tier have minimal to no public disclosure requirements. This tier is typically home to shell companies, defunct entities, or companies with limited operations and financial information. Investors in OTC Other stocks face significantly higher risks due to the lack of transparency and regulatory oversight compared to higher OTC tiers like OTCQB or OTCQX, let alone national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Extreme illiquidity and difficulty in trading shares.
- Lack of public financial disclosure and transparency (Disclosure Status: Unknown).
- Higher susceptibility to fraud and market manipulation due to minimal oversight.
- Difficulty in obtaining reliable information for investment decisions.
- Limited analyst coverage and institutional investor interest.
- Verify current financial statements and audit reports, if any are available.
- Research any past or ongoing regulatory actions or enforcement against the company.
- Investigate the background and legitimacy of management beyond basic names.
- Assess the actual operational status and revenue generation capabilities.
- Examine share structure, outstanding shares, and any potential dilution.
- Scrutinize any claims of partnerships or product development for factual basis.
- Confirm the company's legal standing and registration with state authorities.
- Existence of specific product brands (JW Brands, Chad Enterprises) and product categories (cannabis, CBD, kava, kratom).
- Stated physical headquarters in Coachella, US.
- Identified founding year (2020) and a corporate name change in April 2023.
- Identified CEO (Samuel L. Berry) and employee count (2).
Common Questions About CSTF (Healthcare)
What specific products does CuraScientific Corp offer in the healthcare and wellness market?
CuraScientific Corp. specializes in a diversified portfolio of botanical products aimed at the healthcare and wellness market. Its primary offerings include a range of cannabis products, which are marketed under two distinct brand names: JW Brands and Chad Enterprises. These cannabis products encompass various forms for production, distribution, and retail. Beyond cannabis, the company also provides cannabidiol (CBD) products, which are non-psychoactive compounds derived from cannabis known for their potential therapeutic benefits. Additionally, CuraScientific includes kava and kratom in its product lineup, both of which are botanicals with traditional uses in wellness and relaxation. This multi-product strategy allows the company to address different segments of the growing market for natural and alternative health solutions.
How does CuraScientific Corp's financial performance reflect its position in the specialty drug and botanical market?
CuraScientific Corp.'s current financial performance, as indicated by its metrics, reflects a company in a very early or challenging stage within the specialty drug and botanical market. The company reports an extremely negative profit margin of -15299.2% and a gross margin of -3298.1%. These figures suggest that the company's costs, both direct and operational, significantly outweigh its revenues, indicating substantial unprofitability. A market capitalization of 377K further points to a nascent or illiquid market presence. While the company operates in a sector with high growth potential, these financial indicators highlight significant hurdles in achieving sustainable revenue generation and cost efficiency, which are critical for long-term viability in the competitive healthcare and botanical products industry.
What are the regulatory challenges and opportunities for CSTF in the evolving cannabis and botanical industry?
CuraScientific Corp. operates within a highly dynamic and complex regulatory environment, particularly concerning its cannabis, CBD, kava, and kratom products. The primary challenge stems from the varying legal statuses of cannabis at federal and state levels in the U.S., which creates significant hurdles for interstate commerce, banking, and taxation. Regulatory changes, such as new state legalizations, present opportunities for market expansion but also require substantial investment in compliance and licensing. For CBD, kava, and kratom, regulations regarding labeling, marketing claims, and product safety are also evolving, demanding continuous adaptation. The company must navigate these intricate legal frameworks to ensure product legitimacy, distribution access, and consumer trust, while also being poised to capitalize on any favorable shifts in legislation that could open up new markets or streamline operations.
What are the key factors to evaluate for CSTF?
CuraScientific Corp (CSTF) holds an AI score of 42/100 (low). Not financial advice.
How frequently does CSTF data refresh on this page?
CSTF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CSTF's recent stock price performance?
CuraScientific Corp (CSTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio including cannabis, CBD, kava, and kratom. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSTF overvalued or undervalued right now?
Valuing CuraScientific Corp (CSTF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CSTF?
Before investing in CuraScientific Corp (CSTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited by the provided source data, particularly regarding detailed financial performance, CEO background, and specific market share data.
- Competitor information was not provided in the source data.
- The company's OTC Other tier status implies significant limitations in publicly available information and liquidity.